Direct Healthcare Professional Communication (DHPC) on metamizole-containing medicines: important measures to minimise the serious outcomes of known risk of agranulocytosis
2024.12.09
Active substance: metamizole
The marketing authorisation holders of metamizole-containing medicines would like to inform that patients treated with metamizole-containing medicines should be informed of the early symptoms suggestive of agranulocytosis, including fever, chills, sore throat and painful mucosal changes, especially in the mouth, nose and throat or in the genital or anal region. Patients need to discontinue treatment and seek immediate medical attention if they develop these symptoms at any time during treatment and also shortly after treatment discontinuation.
Download DHPC/Information letter , Download_VeroeffentlichtAm_EN